Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 16/20 | 0.50 |
| ▸ | CA2 | P00918 | 16/20 | 0.50 |
| ▸ | CA9 | Q16790 | 15/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA7 | P43166 | 5/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.48 |
| ▸ | CA3 | P07451 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA6 | P23280 | 4/20 | 0.48 |
| ▸ | CA5A | P35218 | 4/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Busulfan SCHEMBL4373 | 1.00 | TSHR (1.00) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL1931795 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL1335477 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| Busulfan SCHEMBL29364030 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL8592211 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL4952202 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL4298840 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| Busulfan SCHEMBL7195165 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL4954793 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| Busulfan SCHEMBL29911485 | 0.97 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120077048-A | Tricyclic compounds and uses thereof | 诺华股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-117425657-A | Triazolo-pyrimidine analogs for the treatment of diseases associated with inhibition of Wonna syndrome RECzochralski enzyme (WRN) | 诺华股份有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| US-20260130943-A1 | METHODS AND COMPOSITIONS FOR TRANSGENE DELIVERY AND/OR RECONSTITUTING MICROGLIA | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-05-14 | — | — | US | disclosed |
| US-12576110-B2 | Methods and compositions for reconstituting microglia | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4688850-A1 | DISCERNIBLE CELL SURFACE PROTEIN VARIANTS OF CD33 FOR USE IN CELL THERAPY | Universität Basel (CH) | 2026-02-11 | — | — | EP | disclosed |
| CN-120077048-A | Tricyclic compounds and uses thereof | 诺华股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119997943-A | HDAC inhibitors for treating cancers with altered STK11 activity or expression | 探戈医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119925616-A | CD20 therapy, CD22 therapy and combination therapy with CD19 Chimeric Antigen Receptor (CAR) expressing cells | 诺华股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-110461315-B | Treatment and prevention of cytokine release syndrome using chimeric antigen receptor in combination with kinase inhibitors | 诺华股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119744262-A | Piperidinyl-methyl-purinamine D-tartrate, crystalline forms and uses thereof in the treatment of medical diseases and conditions | K36治疗股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| WO-2005082422-A1 | COMBINATION OF AD-P53 AND CHEMOTHERAPY FOR THE TREATMENT OF TUMOURS | INTROGEN THERAPEUTICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005032492-A2 | SITE AND RATE SELECTIVE PRODRUG FORMULATIONS OF D609 WITH ANTIOXIDANT AND ANTICANCER ACTIVITY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2005-04-14 | — | — | WO | disclosed |
| CN-1375332-A | Composition and method for making Akt cancer gene inactivate and activating P38 precell fade-out gene | UNIV TEXAS (US) | 2002-10-23 | — | — | CN | disclosed |
| US-6444872-B1 | FUNGICIDE THERAPY CALIBRATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-09-03 | — | — | US | disclosed |
| EP-1183273-A1 | C-CAM AS AN ANGIOGENESIS INHIBITOR | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000073340-A1 | C-CAM AS AN ANGIOGENESIS INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-12-07 | — | — | WO | disclosed |
| EP-0894139-A1 | SENSITIZATION OF HER-2/NEU OVEREXPRESSING CANCER CELLS TO CHEMOTHERAPY | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1997035012-A1 | SENSITIZATION OF HER-2/NEU OVEREXPRESSING CANCER CELLS TO CHEMOTHERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130943-A1 | METHODS AND COMPOSITIONS FOR TRANSGENE DELIVERY AND/OR RECONSTITUTING MICROGLIA | CX3CR1, LDLR, CSF1R | TSHR 1766/4885USP2 3305/4885KDM4E 3789/4885 |
| US-12576110-B2 | Methods and compositions for reconstituting microglia | CX3CR1, APP, TIMCC | TSHR 2095/4885USP2 2174/4885KDM4E 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.